Difference between revisions of "CT Angiography Biomarker Ctte"
m |
|||
| Line 18: | Line 18: | ||
==Profile Development== | ==Profile Development== | ||
| − | + | *[[Media:QIBA_Atherosclerosis Biomarkers Profile 2018-08-15.docx | QIBA Atherosclerosis Biomarkers Profile 2018-08-15]] | |
==Groundwork Projects== | ==Groundwork Projects== | ||
Revision as of 21:53, 15 August 2018
Co-chairs: Andrew Buckler, MS; Luca Saba, MD; Uwe Joseph Schoepf, MD, FAHA, FSCBT-MR, FNASCI, FSCCT Secretary: Julie Lisiecki
Meetings
Recent Call Summaries:
Project Snapshot - CT Angiography
The group intends to pursue writing quantitative profiles for both Coronary computed tomography angiography (CCTA) and CT angiography (CTA).
Excerpt from the biomarker committee submission form:
The proposed QIBA Atherosclerosis Biomarkers Committee (ABC) will be composed of members from multiple centers of excellence within North America and Europe utilizing different CTA vendors, acquisitions and scanner types, and analysis software vendors. Furthermore, stakeholders from different manufacturers will be included in the committee, who are interested in working closely with the committee in optimizing imaging biomarkers for scientific trials and clinical routine use. The Biomarker Committee will develop technical performance standards to serve as atherosclerosis compositional biomarkers. Moreover, we will involve stakeholders from different societies, in addition to the RSNA, for example ASNR, SCCT, ACR, etc.